Author

Alok Pachori

Observed name: A. Pachori

OpenAlex ID: A5078914218

Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function

2023 · Alex D Hakim, Mustafa Awili, et al. · Clinical & Experimental Immunology · 12

Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

2022 · Umberto Vitolo, Grzegorz S. Nowakowski, et al. · Blood · 7

frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.

2022 · Umberto Vitolo, Grzegorz S. Nowakowski, et al. · Journal of Clinical Oncology · 6

Pb2113: Frontmind: a Phase Iii, Randomized, Double-blind Study of Tafasitamab + Lenalidomide + R-chop Vs R-chop Alone for Newly Diagnosed High-intermediate and High-risk Diffuse Large B-cell Lymphoma

2022 · U. Vitolo, G. S. Nowakowski, et al. · HemaSphere · 3

GS-003 A PNPLA3 antisense oligonucleotide, AZD, for the treatment of MASH in I148M homozygous participants: results from the phase 2b FORTUNA study

2026 · Rohit Loomba, Atsushi Nakajima, et al. · Journal of Hepatology

Works count: 5

Citation count: 28

H-index: 3

I10-index: 1